Bristol Myers (BMY) announced that the European Commission (EC) has approved a label expansion for chimeric antigen receptor (CAR) T cell immunotherapy Abecma.The therapy is now approved in the European Union (EU) in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.Abecma is already approved in the EU, Switzerland, Japan, the United Kingdom and Israel for adult patients with triple-class exposed relapsed or refractory multiple myeloma after three to four or more prior lines of ...